Kerry Group delivers strong H1 2025 performance with volume growth and margin expansion

Published: 31-Jul-2025

Kerry Group has posted a robust set of half-year results for 2025, driven by solid volume growth, margin improvement and strategic investment in innovation-led nutrition

Kerry Group has reported a strong first-half performance for 2025, with revenue rising to €3.5 billion and volume growth of 3.0%, reflecting continued demand for its taste, nutrition and functional ingredient solutions across global markets.

Kerry Group delivers strong H1 2025 performance with volume growth and margin expansion

The Group’s EBITDA rose to €556 million, with EBITDA margins improving by 100 bps to 16.1% — underscoring operational efficiencies and favourable product mix.

Adjusted earnings per share grew 9.8% on a constant currency basis, with free cash flow reaching €309 million, reflecting an 89% cash conversion.

The Group increased its interim dividend by 10.2% to 42.0 cents per share and continued its share buyback programme, repurchasing €256 million worth of stock during the period.

CEO Edmond Scanlon highlighted strong performances in the Americas and emerging markets, bolstered by investments in capacity expansion in APMEA and LATAM, as well as enhancements in Kerry’s taste and bio-fermentation platforms.

Growth was led by the Beverage, Bakery and Snacks categories, with innovation and product renovation in both retail and foodservice channels supporting demand.

Kerry’s proactive health ingredients and sugar- and salt-reduction technologies, including Tastesense, contributed to customer-led innovation across markets.

Notably, Southeast Asia and LATAM delivered 5.6% volume growth, outperforming soft broader market trends.

Regionally, the Americas led with 3.7% volume growth, supported by strong performance in snacks, beverages and bakery, as well as increased demand for healthier formulations.

In Europe, growth was modest at 0.2%, with strong momentum in foodservice and nutritional beverages.

In APMEA, volumes rose by 4.2%, with the Middle East and Southeast Asia showing particular strength.


Kerry’s strategic initiatives included progress on a new Biotechnology Innovation Centre in Leipzig and enzyme capacity expansion in Cork, signalling a continued focus on science-led ingredient development.


Despite ongoing macroeconomic uncertainty, the company maintained its full-year guidance of 7–11% adjusted EPS growth in constant currency, signalling confidence in its ability to sustain growth through innovation, operational excellence and customer partnership.

 

You may also like